A Ministry of Food and Drug Safety data showed that Takeda Pharmaceutical Korea registered the most patents with the ministry in May.

According to the ministry’s drug information website, 14 pharmaceutical companies registered 39 patents last month. Takeda Pharmaceutical Korea registered 10 patents to become the only company to record a double-digit figure.

All 10 patents were for Kynteles, an ulcerative colitis drug -- five each for its prefilled pen and prefilled syringe formulations.

LG Chem followed Takeda Korea’s lead with five patents. Four concerned Zemimet, with the remaining one related to Zemiglo, both combination treatments for diabetes.

Gilead was the third with four patents, with Epclusa, Pfizer, and GSK registering three patents each. In addition, Pfizer registered a patent for Comirnaty, a Covid-19 vaccine, and GSK for Vocabria, a human immunodeficiency virus treatment.

AstraZeneca Korea, Lilly Korea, Jeil Pharmaceutical, SK Chemicals, and Janssen Korea registered two patents each. In addition, AZ Korea registered patents for Fasenra, Lilly Korea for Retevmo, Jeil Pharm for Triferic, SK Chemicals for Remitch ODT, and Janssen Korea for Rekambys.

Abbvie, Amgen, Sama Pharmaceutical, and BeiGene registered one patent each.

Pharmaceutical patent registrations in May